Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $750.00 by Analysts at Cantor Fitzgerald

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price lowered by Cantor Fitzgerald from $785.00 to $750.00 in a research note released on Monday morning,Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the company. Sanford C. Bernstein cut their price target on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating for the company in a research note on Wednesday, April 8th. Barclays dropped their price target on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Guggenheim raised their target price on Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a report on Friday, May 1st. TD Cowen boosted their price target on Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the company a “buy” rating in a report on Thursday, April 23rd. Finally, Wells Fargo & Company lowered their price objective on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating on the stock in a research report on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $790.92.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock traded up $12.26 during trading on Monday, hitting $662.07. 33,993 shares of the company’s stock traded hands, compared to its average volume of 865,687. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. Regeneron Pharmaceuticals has a 1 year low of $537.45 and a 1 year high of $821.11. The stock has a market capitalization of $69.99 billion, a P/E ratio of 16.12, a PEG ratio of 1.44 and a beta of 0.24. The business has a 50-day simple moving average of $652.48 and a 200-day simple moving average of $725.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. The business had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The company’s quarterly revenue was up 19.0% compared to the same quarter last year. During the same period in the previous year, the business earned $8.22 EPS. As a group, analysts forecast that Regeneron Pharmaceuticals will post 37.44 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were paid a dividend of $0.94 per share. The ex-dividend date of this dividend was Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.16%.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the transaction, the director directly owned 17,503 shares of the company’s stock, valued at approximately $12,343,815.72. This trade represents a 0.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently modified their holdings of REGN. Basecamp Wealth Advisors LLC lifted its position in Regeneron Pharmaceuticals by 23.8% during the first quarter. Basecamp Wealth Advisors LLC now owns 203 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 39 shares during the period. Sapient Capital LLC acquired a new stake in Regeneron Pharmaceuticals in the 1st quarter valued at $251,000. Carmignac Gestion increased its holdings in Regeneron Pharmaceuticals by 133.3% in the 1st quarter. Carmignac Gestion now owns 116,571 shares of the biopharmaceutical company’s stock worth $90,015,000 after acquiring an additional 66,600 shares in the last quarter. Militia Capital Management LLC purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at $2,318,000. Finally, Parallel Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 11.3% in the first quarter. Parallel Advisors LLC now owns 1,107 shares of the biopharmaceutical company’s stock valued at $856,000 after purchasing an additional 112 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.